MA11.02 KEYNOTE-042 China Study: First-Line Pembrolizumab vs Chemotherapy in Chinese Patients with Advanced NSCLC with PD-L1 TPS ≥1%
JOURNAL OF THORACIC ONCOLOGY（2019）
关键词
PD-L1,Pembrolizumab,Chemotherapy
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要